Highly Sensitive IBD profile for identifying patients with Inflammatory Bowel Disease

**Novel serological markers** for inflammatory bowel disease (IBD) improve sensitivity and specificity to aid in differential diagnosis and provide valuable prognostic information about disease behavior.

**Scientific Expertise**

Profile developed with only those markers that have been established in published peer reviewed journals and are clinically relevant. Crohn’s disease risk levels and prognostic information validated prospectively in adults and children. Interpretive reports include suggestive disease form and risk stratification for CD patients.

**Clinical Application**

Six-marker IBD profile identifies and differentiates patients with ulcerative colitis (UC) and Crohn’s disease (CD) from other non-inflammatory gastrointestinal diseases.

Reported up to 97% specificity in differentiating UC from CD\textsuperscript{1,2,3}

Reported up to 70% specificity in identifying patients with UC\textsuperscript{4,5}

Reported up to 85.5% sensitivity in identifying patients with CD using multiple markers\textsuperscript{6}

56.4% Sensitivity in identifying CD patients who are anti Saccharomyces cerevisiae antibody (ASCA) negative\textsuperscript{6}

Three prognostic levels for CD severity are provided, allowing for improved treatment decisions\textsuperscript{7,8,9}

Test combination formulated to be appropriate and cost effective for patients.

**Committed to Quality**

The management and staff of Glycominds Diagnostics are committed to meeting customer expectations and all relevant regulatory requirements, while continuously improving the quality performance in every facet of our operations. All this is possible by maintaining our high standards due to our state of the art research, production facilities, and highly qualified staff.
Receiver operating characteristic (ROC) curves of the seven anti-glycan markers (Chron’s disease vs ulcerative colitis)

Of the 178 CD patients who were sero negative for both gASCA IgG and gASCA IgA, 6.74 % were positive for anti-L and 5.62 % were positive for anti-C.

Previous studies showed that ALCA, ACCA and AMCA identify 44% of ASCA sero negative CD patients.

All kits are Quick and Easy to use with short incubation times and ready-to-use reagents.

Also, all our IBDX kits have break-a-well strips allowing high flexibility and economic use.

References